ClinicalTrialsFinder
RecruitingPhase 4NCT06003348

Hydroxycitrate: A Novel Therapy for Calcium Phosphate Urinary Stones

Sponsor

University of Texas Southwestern Medical Center

Enrollment

25 participants

Start Date

Dec 13, 2023

Study Type

INTERVENTIONAL

Conditions

Calcium Phosphate Kidney Stones

Summary

This study tests whether hydroxycitrate, a molecule closely related to citrate, can reduce calcium phosphate stone recurrence.

Eligibility

Min Age: 21 YearsMax Age: 99 Years

Inclusion Criteria1

  • \- Calcium Phosphate stone formers

Exclusion Criteria7

  • History of recurrent urinary tract infections
  • Chronic diarrhea
  • Estimated Glomerular Filtration Rate (eGFR) < 45 ml/min/1.73 m2
  • History of primary hyperparathyroidism
  • Hypokalemia
  • Hyperkalemia
  • Pregnancy

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIETARY_SUPPLEMENTOHCit- standard dose

Hydroxycitrate Over-the-counter supplement, not FDA approved or regulated.

DRUGPotassium Citrate

10 mEq Extended-release tablets for oral use

DRUGPlacebo

Placebo

DIETARY_SUPPLEMENTOHCit- low dose

Hydroxycitrate Over-the-counter supplement, not FDA approved or regulated.

Locations(1)

UT Southwestern Medical Center

Dallas, Texas, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06003348